The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia were lower on Monday, as shares on a new Nasdaq-style technology board on the Shanghai Stock Exchange skyrocketed on their debut day.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Jim Cramer is in complete awe the power of Valeant, and its incredible 14 percent move higher on Monday. Especially considering that it hasn't even combined with Salix yet, an acquisition announced on Sunday.
Valeant announced quarterly earnings a day earlier than expected, and Cramer was blown away.
"I am shocked at how much better it is doing than we thought," said the "Mad Money" host.
Analysts expected to hear organic growth of approximately 12 percent, $2.2 billion in revenues and $600 million in cash flow. Instead, Valeant delivered 16 percent organic growth, $2.3 billion in revenue and cash flow of $624 million. Talk about blowing the lid off of earnings!
Cramer attributes the strength of Valeant not only to its earnings, but also to the fact that it excels at making strategic acquisitions. The Bausch & Lomb acquisition in 2013 proved to be profitable, and Valeant's Top 20 global brands are doing very well.
Allergan previously fought being acquired by Valeant; Allergan dedicates a significant portion of its budget to research and development, while Valeant does not.
"But it sure doesn't seem like it is hurting Valeant. Its new products are doing so well," said Cramer.
With its pending acquisition of Salix, Valeant expects to save $500 million in corporate overhead reductions and cutbacks in R&D. The deal is expected to be completed within six months.
Read more from Mad Money with Jim Cramer
Cramer Remix: This stock is on a run
Cramer's game plan: Expect major news on this
Cramer: The sexy stock giving you glamorous gains
And while the Street expects $10 a share next year from Salix, Cramer wouldn't be surprised if it got $12 a share. Additionally, Salix has other gastrointestinal products down the pipeline that could add even more value.
Cramer commented on the potential value of Valeant, stating, "This is the fastest growing major pharmaceutical. It is easier to see that it could trade to $240 if it executes and the irritable bowel syndrome drug gets approved. It's not a pipe-dream. It's a reality."